{"id":"https://openalex.org/W4247249153","doi":"https://doi.org/10.1158/1538-7445.sabcs18-3642","title":"Abstract 3642: Combination nanotherapy using the PARP inhibitor talazoparib and cyclin dependent kinase inhibitor dinaciclib","display_name":"Abstract 3642: Combination nanotherapy using the PARP inhibitor talazoparib and cyclin dependent kinase inhibitor dinaciclib","publication_year":2019,"publication_date":"2019-07-01","ids":{"openalex":"https://openalex.org/W4247249153","doi":"https://doi.org/10.1158/1538-7445.sabcs18-3642"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.sabcs18-3642","doi":"https://doi.org/10.1158/1538-7445.sabcs18-3642","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs18-3642","pdf_url":null,"source":{"id":"https://openalex.org/S4306505626","display_name":"Cancer Chemistry","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemistry","raw_type":"proceedings-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5033547791","display_name":"Paige Baldwin","orcid":"https://orcid.org/0000-0002-0146-7177","observed_orcids":["https://orcid.org/0000-0002-0146-7177"]},"institutions":[{"id":"https://openalex.org/I12912129","display_name":"Northeastern University","ror":"https://ror.org/04t5xt781","country_code":"US","type":"education","lineage":["https://openalex.org/I12912129"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paige Baldwin","raw_affiliation_strings":["Northeastern University, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Northeastern University, Boston, MA","institution_ids":["https://openalex.org/I12912129"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059047722","display_name":"Adrienne M. Orriols","orcid":"https://orcid.org/0000-0002-3681-4896","observed_orcids":["https://orcid.org/0000-0002-3681-4896"]},"institutions":[{"id":"https://openalex.org/I12912129","display_name":"Northeastern University","ror":"https://ror.org/04t5xt781","country_code":"US","type":"education","lineage":["https://openalex.org/I12912129"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Adrienne Orriols","raw_affiliation_strings":["Northeastern University, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Northeastern University, Boston, MA","institution_ids":["https://openalex.org/I12912129"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5101987852","display_name":"Srinivas Sridhar","orcid":"https://orcid.org/0000-0003-1605-0734","observed_orcids":["https://orcid.org/0000-0003-1605-0734"]},"institutions":[{"id":"https://openalex.org/I12912129","display_name":"Northeastern University","ror":"https://ror.org/04t5xt781","country_code":"US","type":"education","lineage":["https://openalex.org/I12912129"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Srinivas Sridhar","raw_affiliation_strings":["Northeastern University, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Northeastern University, Boston, MA","institution_ids":["https://openalex.org/I12912129"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I12912129"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"3642","last_page":"3642"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.7148000001907349,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.7148000001907349,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.26899999380111694,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10725","display_name":"RNA Interference and Gene Delivery","score":0.0031999999191612005,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/talazoparib","display_name":"talazoparib","score":0.9319999814033508},{"id":"https://openalex.org/keywords/dinaciclib","display_name":"dinaciclib","score":1.0},{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.9179999828338623},{"id":"https://openalex.org/keywords/cyclin-dependent-kinase-inhibitors","display_name":"cyclin-dependent kinase inhibitors","score":0.9340000152587891},{"id":"https://openalex.org/keywords/nanoparticle-drug-delivery","display_name":"nanoparticle drug delivery","score":0.9290000200271606},{"id":"https://openalex.org/keywords/parp-inhibitor-resistance","display_name":"PARP inhibitor resistance","score":0.8090000152587891},{"id":"https://openalex.org/keywords/drug-sensitization","display_name":"drug sensitization","score":0.6240000128746033},{"id":"https://openalex.org/keywords/homologous-recombination","display_name":"homologous recombination","score":0.8069999814033508},{"id":"https://openalex.org/keywords/mda-mb-231-breast-cancer","display_name":"MDA-MB-231 breast cancer","score":0.7850000262260437},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8080000281333923},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.656000018119812},{"id":"https://openalex.org/keywords/hematological-toxicity","display_name":"hematologic toxicity","score":0.6919999718666077},{"id":"https://openalex.org/keywords/orthotopic-xenograft-model","display_name":"orthotopic xenograft","score":0.8140000104904175},{"id":"https://openalex.org/keywords/drug-half-life-extension","display_name":"drug half-life extension","score":0.46700000762939453}],"concepts":[{"id":"https://openalex.org/C2779138821","wikidata":"https://www.wikidata.org/wiki/Q7118227","display_name":"PARP inhibitor","level":5,"score":0.8711514472961426},{"id":"https://openalex.org/C124320809","wikidata":"https://www.wikidata.org/wiki/Q46292","display_name":"Cyclin-dependent kinase","level":4,"score":0.6247363090515137},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5763182044029236},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5403080582618713},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.4151998460292816},{"id":"https://openalex.org/C134935766","wikidata":"https://www.wikidata.org/wiki/Q210538","display_name":"DNA repair","level":3,"score":0.41030141711235046},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.38705867528915405},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3665377199649811},{"id":"https://openalex.org/C182979987","wikidata":"https://www.wikidata.org/wiki/Q3907241","display_name":"Poly ADP ribose polymerase","level":4,"score":0.3228006958961487},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.31974130868911743},{"id":"https://openalex.org/C29537977","wikidata":"https://www.wikidata.org/wiki/Q188941","display_name":"Cell cycle","level":3,"score":0.1655253767967224},{"id":"https://openalex.org/C552990157","wikidata":"https://www.wikidata.org/wiki/Q7430","display_name":"DNA","level":2,"score":0.13685691356658936},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.11373090744018555},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.06679904460906982},{"id":"https://openalex.org/C82381507","wikidata":"https://www.wikidata.org/wiki/Q416878","display_name":"Polymerase","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.sabcs18-3642","doi":"https://doi.org/10.1158/1538-7445.sabcs18-3642","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs18-3642","pdf_url":null,"source":{"id":"https://openalex.org/S4306505626","display_name":"Cancer Chemistry","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemistry","raw_type":"proceedings-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.979200005531311,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4393119685","https://openalex.org/W7221408006","https://openalex.org/W2741569844","https://openalex.org/W4242823469","https://openalex.org/W2992138944","https://openalex.org/W2504216116","https://openalex.org/W3161226323","https://openalex.org/W2887994141","https://openalex.org/W2399980135","https://openalex.org/W1992065025"],"abstract_inverted_index":{"Introduction:":[0],"PARP":[1,20,43,80,85,309,365],"inhibitors":[2,44,52],"exploit":[3],"defects":[4,37,183],"in":[5,48,111,167,169,199,245,289,340],"DNA":[6,35,181],"repair":[7,36,182],"pathways":[8],"to":[9,25,55,73,84,115,128,171,184,230,308,315],"selectively":[10],"target":[11,26],"cancerous":[12],"cells.":[13],"As":[14,237],"such,":[15],"Talazoparib":[16,95,150],"(TLZ),":[17],"a":[18,23,30,63,104,126,176,238],"potent":[19,64],"inhibitor,":[21,69],"offers":[22],"way":[24],"the":[27,130,138,189,214,217,234,252,255,266,269,290,337,364,378],"biology":[28],"of":[29,32,89,106,133,149,188,205,216,225,254,268,274,286,296,320,377],"number":[31],"cancers":[33],"with":[34,50,178],"until":[38],"these":[39,107,134],"tumors":[40,78,83,307],"develop":[41],"resistance.":[42],"must":[45],"be":[46],"used":[47],"combination":[49,105,145,168,187,253,267,291,295],"other":[51],"or":[53,265],"chemotherapeutics":[54],"reverse":[56],"resistance":[57],"and":[58,79,96,118,136,152,157,159,166,197,207,298,344,368],"sensitize":[59,74,175],"non-responsive":[60],"tumors.":[61],"Dinaciclib,":[62],"cyclin":[65,369],"dependent":[66,370],"kinase":[67,371],"(CDK)":[68],"has":[70,300,324],"been":[71],"shown":[72],"both":[75,99],"BRCA":[76],"wild-type":[77],"inhibitor":[81,366,372],"resistant":[82],"inhibition":[86,310],"through":[87],"disruption":[88],"homologous":[90],"recombination.":[91],"In":[92,250],"clinical":[93],"trials,":[94],"Dinaciclib":[97,153,226],"have":[98,332],"demonstrated":[100],"hematologic":[101,275],"toxicities,":[102],"suggesting":[103],"drugs":[108,135,339],"would":[109],"result":[110],"compounded":[112],"toxicity,":[113],"leading":[114],"dose":[116,224],"reduction":[117],"an":[119,302],"ineffective":[120],"combination.":[121],"Nanoparticle":[122],"delivery":[123],"systems":[124],"offer":[125],"means":[127],"modify":[129],"toxicity":[131,198,288],"profiles":[132],"enhance":[137],"therapeutic":[139],"window,":[140],"therefore":[141],"allowing":[142],"for":[143,195,305,326,381],"effective":[144,244,260,303,335],"treatment.Methods:":[146],"Separate":[147],"nanoformulations":[148,191,257,323,331],"(NanoTLZ)":[151],"(NanoDCB)":[154],"were":[155,163,209,283,345],"optimized,":[156],"pharmacokinetics":[158],"pharmacodynamics":[160],"assessed.":[161],"Nanoformulations":[162],"tested":[164],"alone":[165],"vitro":[170,246],"ensure":[172],"NanoDCB":[173,208,241,297],"could":[174],"model":[177],"no":[179,284],"known":[180],"NanoTLZ.":[185],"The":[186,294,318],"two":[190,256,270,321],"was":[192,242,258,350],"then":[193],"assessed":[194],"efficacy":[196],"orthotopic":[200],"MDA-MB-231":[201,228],"xenografts.Results:":[202],"Robust":[203],"formulations":[204],"NanoTLZ":[206,299],"developed.":[210],"Each":[211],"nanoformulation":[212,264],"extended":[213],"half-life":[215],"drug":[218],"it":[219],"encapsulates.":[220],"A":[221],"constant":[222],"low":[223],"sensitized":[227],"cells":[229],"Talazoparib,":[231],"significantly":[232],"lowering":[233],"IC50":[235],"value.":[236],"single":[239,263],"agent":[240],"more":[243,259,334],"than":[247,261,336],"free":[248,271,338],"Dinaciclib.":[249],"vivo,":[251],"either":[262],"drugs.":[272],"Assessments":[273],"toxicities":[276],"are":[277,312],"underway,":[278],"but":[279],"thus":[280],"far,":[281],"there":[282],"signs":[285],"gross":[287],"therapy":[292],"group.Conclusions:":[293],"provided":[301],"method":[304],"sensitizing":[306],"that":[311],"otherwise":[313],"nonresponsive":[314],"this":[316],"therapy.":[317],"development":[319],"separate":[322],"allowed":[325],"tailored":[327],"dosing.":[328],"These":[329],"long-circulating":[330],"proven":[333],"stabilizing":[341],"tumor":[342],"growth":[343],"well":[346],"tolerated.":[347],"This":[348],"work":[349],"supported":[351],"by":[352],"ARMY/W81XWH-16-1-0731.Citation":[353],"Format:":[354],"Paige":[355],"Baldwin,":[356],"Adrienne":[357],"Orriols,":[358],"Srinivas":[359],"Sridhar.":[360],"Combination":[361],"nanotherapy":[362],"using":[363],"talazoparib":[367],"dinaciclib":[373],"[abstract].":[374],"In:":[375],"Proceedings":[376],"American":[379],"Association":[380],"Cancer":[382,396],"Research":[383],"Annual":[384],"Meeting":[385],"2019;":[386],"2019":[387],"Mar":[388],"29-Apr":[389],"3;":[390],"Atlanta,":[391],"GA.":[392],"Philadelphia":[393],"(PA):":[394],"AACR;":[395],"Res":[397],"2019;79(13":[398],"Suppl):Abstract":[399],"nr":[400],"3642.":[401]},"counts_by_year":[],"updated_date":"2026-10-01T08:54:57.152042","created_date":"2022-05-12T00:00:00"}